Healthcare provider profile · identity verified

Christopher L Mathur, DO

Internal Medicine · BETHLEHEM, PA · NPI 1992760599

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	577	161
Rosuvastatin Calcium	Rosuvastatin Calcium	557	150
Levothyroxine Sodium	Levothyroxine Sodium	545	107
Atorvastatin Calcium	Atorvastatin Calcium	536	152
Sertraline Hcl	Sertraline Hcl	261	62
Omeprazole	Omeprazole	258	73
Lisinopril	Lisinopril	242	62
Metoprolol Succinate	Metoprolol Succinate	198	56
Losartan Potassium	Losartan Potassium	190	51
Gabapentin	Gabapentin	187	43
Simvastatin	Simvastatin	172	38
Hydrochlorothiazide	Hydrochlorothiazide	162	41
Fluticasone Propionate	Fluticasone Propionate	161	77
Pravastatin Sodium	Pravastatin Sodium	159	40
Pantoprazole Sodium	Pantoprazole Sodium	157	38
Metformin Hcl	Metformin Hcl	155	42
Famotidine	Famotidine	149	41
Metformin Hcl Er	Metformin Hcl	134	37
Escitalopram Oxalate	Escitalopram Oxalate	127	35
Eliquis	Apixaban	126	28
Jardiance	Empagliflozin	125	29
Metoprolol Tartrate	Metoprolol Tartrate	122	30
Tamsulosin Hcl	Tamsulosin Hcl	120	35
Furosemide	Furosemide	106	35
Albuterol Sulfate Hfa	Albuterol Sulfate	105	45
Potassium Chloride	Potassium Chloride	99	28
Clopidogrel	Clopidogrel Bisulfate	92	23
Atenolol	Atenolol	84	22
Trazodone Hcl	Trazodone Hcl	77	21
Alprazolam	Alprazolam	75	15
Buspirone Hcl	Buspirone Hcl	71	21
Venlafaxine Hcl Er	Venlafaxine Hcl	70	16
Allopurinol	Allopurinol	69	16
Duloxetine Hcl	Duloxetine Hcl	64	23
Synthroid	Levothyroxine Sodium	59	15
Zolpidem Tartrate	Zolpidem Tartrate	57	13
Xarelto	Rivaroxaban	53	15
Ezetimibe	Ezetimibe	51	16
Ozempic	Semaglutide	51	13
Mounjaro	Tirzepatide	46	suppressed
Valsartan	Valsartan	46	suppressed
Lorazepam	Lorazepam	41	20
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	39	14
Finasteride	Finasteride	38	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	38	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	37	11
Warfarin Sodium	Warfarin Sodium	37	suppressed
Amoxicillin	Amoxicillin	36	32
Januvia	Sitagliptin Phosphate	36	13
Oxybutynin Chloride Er	Oxybutynin Chloride	36	suppressed
Alendronate Sodium	Alendronate Sodium	34	suppressed
Carvedilol	Carvedilol	34	13
Ketoconazole	Ketoconazole	33	21
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	32	suppressed
Montelukast Sodium	Montelukast Sodium	31	11
Paroxetine Hcl	Paroxetine Hcl	31	suppressed
Spironolactone	Spironolactone	31	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	30	13
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	30	suppressed
Clonazepam	Clonazepam	28	suppressed
Azithromycin	Azithromycin	27	25
Citalopram Hbr	Citalopram Hydrobromide	26	suppressed
Klor-Con M20	Potassium Chloride	25	suppressed
Cephalexin	Cephalexin	24	18
Myrbetriq	Mirabegron	24	suppressed
Rivastigmine	Rivastigmine Tartrate	24	suppressed
Donepezil Hcl	Donepezil Hcl	23	suppressed
Mometasone Furoate	Mometasone Furoate	23	14
Ramipril	Ramipril	23	suppressed
Bupropion Xl	Bupropion Hcl	22	suppressed
Glipizide	Glipizide	22	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	22	suppressed
Tradjenta	Linagliptin	22	suppressed
Benazepril Hcl	Benazepril Hcl	21	suppressed
Celecoxib	Celecoxib	21	suppressed
Irbesartan	Irbesartan	21	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	21	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	20	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	20	suppressed
Torsemide	Torsemide	19	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	18	suppressed
Fosinopril Sodium	Fosinopril Sodium	18	suppressed
Prednisone	Prednisone	18	suppressed
Hydralazine Hcl	Hydralazine Hcl	17	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	17	suppressed
Diclofenac Sodium	Diclofenac Sodium	16	suppressed
Divalproex Sodium	Divalproex Sodium	16	suppressed
Farxiga	Dapagliflozin Propanediol	16	suppressed
Nystatin	Nystatin	16	12
Sucralfate	Sucralfate	16	suppressed
Tizanidine Hcl	Tizanidine Hcl	16	suppressed
Desloratadine	Desloratadine	15	suppressed
Diazepam	Diazepam	15	suppressed
Enalapril Maleate	Enalapril Maleate	15	suppressed
Tramadol Hcl	Tramadol Hcl	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	suppressed
Baclofen	Baclofen	14	suppressed
Chlorthalidone	Chlorthalidone	14	suppressed
Glimepiride	Glimepiride	14	suppressed
Lactulose	Lactulose	14	suppressed
Methylprednisolone	Methylprednisolone	14	13
Flecainide Acetate	Flecainide Acetate	13	suppressed
Ibuprofen	Ibuprofen	13	suppressed
Indapamide	Indapamide	13	suppressed
Methocarbamol	Methocarbamol	13	suppressed
Naltrexone Hcl	Naltrexone Hcl	13	suppressed
Novolog Flexpen	Insulin Aspart	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	suppressed
Eszopiclone	Eszopiclone	12	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	12	suppressed
Temazepam	Temazepam	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Oxycodone Hcl	Oxycodone Hcl	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error